What is the recommended management for a patient with urticarial vasculitis presenting with vesicular eruptions and concurrent membranous nephropathy?

Management of Urticarial Vasculitis with Vesicular Eruptions and Membranous Nephropathy

For a patient presenting with urticarial vasculitis, vesicular eruptions, and concurrent membranous nephropathy, initiate combination therapy with glucocorticoids plus immunosuppressive agents (rituximab or cyclophosphamide), as this dual-organ involvement represents hypocomplementemic urticarial vasculitis syndrome (HUVS) requiring aggressive systemic treatment.

Diagnostic Confirmation and Risk Stratification

First, confirm the diagnosis through:

• Skin biopsy showing leukocytoclastic vasculitis (not just chronic urticaria) 1
• Complement levels (C3, C4, C1q) - hypocomplementemia indicates systemic disease with worse prognosis 2
• Anti-C1q antibodies - diagnostic for HUVS 2
• Renal biopsy to characterize the glomerular pathology

The presence of both cutaneous vasculitis and membranous nephropathy indicates systemic involvement, which occurs in approximately 13% of HUVS cases and carries significant morbidity risk 2. Hypocomplementemic disease is much more likely to have systemic manifestations affecting kidneys, joints, lungs, and eyes 3, 4.

Treatment Algorithm

Immediate Management (First-Line)

Combination immunosuppression is mandatory - monotherapy is insufficient for dual-organ involvement:

1. Glucocorticoids (cornerstone therapy):

   • High-dose methylprednisolone initially
   • Transition to oral prednisone with gradual taper
   • This has proven effective in case reports 3, 5

2. Plus Rituximab (preferred first-line immunosuppressive):

   • Recognized as first-line therapy for membranous nephropathy with progressive disease 6, 7
   • Two doses of rituximab showed marked improvement in similar cases 8
   • Allows monitoring of immunologic activity 7

Alternative Immunosuppressive Options

If rituximab is unavailable or contraindicated:

• Cyclophosphamide: Effective for both HUVS and membranous nephropathy 8

  • Oral cyclophosphamide for maintenance after initial control 3
  • Low-dose IV cyclophosphamide (Euro-Lupus regimen) followed by azathioprine maintenance 4

• Cyclosporine: Calcineurin inhibitor option for membranous nephropathy 6

  • Can be combined with omalizumab for refractory urticarial component 9

Supportive Care (Mandatory Concurrent Therapy)

Based on KDIGO guidelines for membranous nephropathy 6:

• Renin-angiotensin system inhibitors (ACE inhibitors or ARBs)
• Lipid-lowering agents (statins)
• Diuretics for edema management
• Anticoagulation consideration if severe nephrotic syndrome

Additional Considerations

Hydroxychloroquine may be added, particularly if there are features suggesting underlying connective tissue disease (positive ANA, anti-SSa antibodies) 2, 4. This was effective in one case with low-dose steroids alone 2.

Critical Pitfalls to Avoid

1. Do not treat as simple chronic urticaria: The diagnostic algorithm clearly distinguishes urticarial vasculitis (wheals lasting >24 hours) from chronic spontaneous urticaria 1. Missing this distinction delays appropriate immunosuppression.

2. Do not use antihistamines alone: While appropriate for chronic urticaria, they are insufficient for vasculitis with systemic involvement.

3. Do not delay renal biopsy: Membranous nephropathy associated with HUVS can present as various glomerular patterns (membranoproliferative in 88% of cases, membranous, or mixed patterns) 2, 5. Histology guides intensity of treatment.

4. Monitor for life-threatening complications: Exclude rapidly progressive glomerulonephritis requiring plasmapheresis 8. The exception to rituximab first-line is life-threatening nephrotic syndrome or rapidly deteriorating kidney function 7.

Monitoring Response

• Complement levels and anti-C1q antibodies track disease activity 2
• Urinalysis for proteinuria (52% of cases) and hematuria (60% of cases) 2
• Renal function - kidney failure occurs in only 22% with fairly good prognosis if treated 2
• Skin lesions should improve within days to weeks 3, 4

The combination approach has demonstrated complete remission in reported cases, with clearance of skin lesions and renal remission 3, 4. Renal prognosis is generally favorable with appropriate immunosuppression 2.